Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | AQP1 | P29972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8220449 | 0.92 | SLC6A4 (0.43) | SLC6A2SLC6A4SLC6A3AQP1 | |
| SCHEMBL14364276 | 0.92 | HTR7 (0.42) | SLC6A2SLC6A4SLC6A3AQP1 | |
| SCHEMBL8221211 | 0.89 | ADRA1D (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8221249 | 0.87 | ADRA1D (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8225821 | 0.83 | AQP1 (0.40) | SLC6A2SLC6A4SLC6A3AQP1 | |
| SCHEMBL8220862 | 0.82 | AQP1 (0.38) | SLC6A2SLC6A4SLC6A3AQP1 | |
| SCHEMBL6107379 | 0.81 | HTT (0.40) | HTR2AHTR2CHTR2BAQP1 | |
| SCHEMBL14364285 | 0.81 | AQP1 (0.41) | SLC6A2SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL8220442 | 0.80 | AQP1 (0.50) | SLC6A2SLC6A4SLC6A3AQP1 | |
| SCHEMBL8225835 | 0.80 | AQP1 (0.43) | AQP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | SLC6A2 262/4885SLC6A4 213/4885SLC6A3 137/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | SLC6A2 353/4885SLC6A4 290/4885SLC6A3 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.